Table 3

Summary of change in total PsA-modified vdH-S score from wk 0 to wk 24, wk 24 to wk 52, and wk 0 to wk 52; integrated data analysis of randomised patients in the PSUMMIT-1 and PSUMMIT-2 studies

Treatment groupWk 0–24Wk 24–52Wk 0–52
Placebo → 45 mg*, n269269269
 Mean±SD1.1±4.10.1±2.11.2±5.4
Ustekinumab 45 mg, n308308308
 Mean±SD0.4±2.10.2±1.80.6±2.6
 Ustekinumab 45 mg only, n252252
 Mean±SD0.3±2.00.1±1.8
 Early escape (45 mg→90 mg), n5656
 Mean±SD0.8±2.40.4±2.2
Ustekinumab 90 mg, n309309309
 Mean±SD0.4±2.40.3±2.10.7±3.7
 Ustekinumab 90 mg only, n261261
 Mean±SD0.2±1.50.2±1.6
 Early escape (90 mg→90 mg), n4848
 Mean±SD1.6±4.90.5±3.7
  • *Patients who did not receive ustekinumab are excluded.

  • Patients who met early escape criteria at wk 16.

  • Patients who did not meet early escape criteria at wk 16.

  • PsA, psoriatic arthritis; vdH-S, van der Heijde-Sharp; wk, week.